These studies demonstrate relatively rapid association of plasmin with thrombospondin and the effects of this interaction on plasmin activity towards D-Val-L-Leu-L-Lys p-nitroanilide hydrochloride (S-2251) and the proteinase inhibitors a2-antiplasmin (a2AP) and a2-macroglobulin (a.2M). Binding of plasmin to thrombospondin reached an apparent reversible equilibrium within 3 min at 22 'C. The amidase activity of bound plasmin was inhibited. An analysis of S-2251 hydrolysis indicated that thrombospondin is a linear mixed-type plasmin inhibitor. The dissociation constant (KD) for the binding of plasmin to thrombospondin was 0.5 ,M, assuming one plasmin binding site per thrombospondin homotrimer. Plasmin and miniplasmin slowly cleaved thrombospondin, yielding products which were comparable with those generated by other proteinases. Tranexamic acid inhibited the digestion of thrombospondin by plasmin and miniplasmin, suggesting an important role for the kringle-5 domain in this process. When plasmin was incubated INTRODUCTION
INTRODUCTION
The digestion of fibrin and fibrinogen by plasmin has been well characterized; however, recent studies have identified other physiologically significant plasmin substrates including growth factors, metalloproteinase zymogens and extracellular-matrix proteins (for review see [1] ). The intact structure of [Glul] plasminogen includes 791 amino-acid residues which form a Cterminal catalytic domain preceded by five triple-disulphidebounded kringle domains [2, 3] . The kringle domains mediate non-covalent binding interactions between plasmin(ogen) and numerous macromolecules including fibrin, cell-surface receptors, and matrix proteins. Plasminogen activation results from the cleavage of a single Arg560-Val561 peptide bond [2] . Activation occurs more readily when plasminogen is bound to fibrin or other macromolecules [4] [5] [6] . Furthermore, plasmin bound to fibrin [7, 8] or cell surfaces [1, 9] is protected from inhibition by the primary plasmin inhibitors 2-antiplasmin (a2AP) and ac2-macroglobulin (a2M). These complex interactions limit the proteolytic activity of plasmin to sites where this activity is necessary.
Thrombospondin-1 is a homotrimeric 420 000-Mr glycoprotein and apparently the product of a single locus in the human genome [10, 11] . Upon activation, high levels of thrombospondin are released from platelet a-granules and incorporated into the polymerizing fibrin clot [12] . By interacting with fibrinogen and platelet receptors, thrombospondin stabilizes platelet aggregates first with thrombospondin and then with a2AP, plasmin that was apparently bound to thrombospondin reacted with a2AP at a decreased rate; however, within 20 min, all of the plasmin was recovered in complex with a2AP. Similar results were obtained with a2M. Transfer of plasmin from thrombospondin to x2AP or a2M probably required plasmin-thrombospondin-complex dissociation. A low level of reaction of a2AP with thrombospondin-associated plasmin could not be ruled out. These results demonstrate that the activity of plasmin, when bound to thrombospondin, is greatly diminished or eliminated. The plasmin-thrombospondin complex, which is formed within 3 min, is fully reversible and the associated plasmin is in a latent form protected from proteinase inhibitors. Therefore, thrombospondin may regulate plasmin activity in a manner which is distinct from conventional proteinase inhibitors and other extracellular-matrix proteins. [13, 14] . In addition, thrombospondin, which is synthesized by both normal and neoplastic cells, functions in cellular adhesion, motility and differentiation [14, 15] . Since plasmin and thrombospondin co-exist in the same microenvironments (fibrin clot, basement membrane, extracellular matrix) and affect the same processes (cell motility, growth, tumour metastasis) the interaction of plasmin with thrombospondin may be of great importance.
Silverstein et al. [6, 16] demonstrated that plasminogen binds thrombospondin and that binding enhances the rate of plasminogen activation by tissue-plasminogen activator (t-PA). Furthermore, these investigators demonstrated that thrombospondin-associated plasmin is protected from inhibition by a2AP. Based on studies with lysine analogues, an important role for the high-affinity lysine-binding site (located in the kringle-I or KI domain of plasminogen) in mediating the plasmin(ogen)-thrombospondin interaction was suggested. DePoli et al. [17] proposed that the plasminogen-thrombospondin interaction occurs via kringle 5 (KS) since they were able to demonstrate binding of 1251-thrombospondin to an elastase-digestion fragment of plasminogen (miniplasminogen) which contains only K5 and the catalytic domain. The studies presented by Depoli et al. [17] were performed using plasminogen which was denatured and/or blotted on nitrocellulose, and in some experiments binding was not inhibited by lysine. Therefore, the importance of the various plasmin(ogen) kringle domains in the plasmin(ogen)-thrombospondin interaction is not clearly resolved.
Abbreviations used: a2AP, a2-antiplasmin; a2M, a2-macroglobulin; t-PA, tissue-plasminogen activator; PNPGB, p-nitrophenyl p'-guanidinobenzoate hydrochloride; BAPNA, Nt-benzoyl-DL-arginine p-nitroanilide hydrochloride; TEA, tranexamic acid; eAHA, e-amino-N-hexanoic acid; PPACK, D-Phe-LPro-L-Arg-chloromethyl ketone; S-2251, D-Val-L-Leu-L-Lys p-nitroanilide hydrochloride; K5, kringle-5 domain; TBS-C-T, buffer containing 50mM
Tris/HCI, 150 mM NaCI, 1 mM CaCI2, 0.05% Tween 80, pH 7.6; to.51 time required for 50% inhibition of initial plasmin activity; tO951 time required for 95% inhibition of initial plasmin activity.
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The studies by Silverstein et al. [16] demonstrated that binding of plasmin to thrombospondin does not directly affect plasmin activity. Recently, however, this conclusion has been brought into question. Based on fibrin plate-lysis studies and chromogenic-substrate-hydrolysis experiments, Hogg et al. [18] proposed that plasmin binds slowly but irreversibly to thrombospondin. As a result of binding, plasmin is completely inactivated so that, in effect, thrombospondin may be considered a slow tightbinding plasmin inhibitor (KD < 1.0 nM).
In this investigation, we demonstrate relatively rapid association of plasmin with thrombospondin. As a result of this interaction, which reaches an apparent equilibrium in approx. 3 min, the plasmin is completely or almost completely inhibited. Our conclusion, that thrombospondin inhibits plasmin, supports the study by Hogg et al. [18] ; however, the interaction reported here was reversible and of significantly lower affinity (0.5 ,uM) than previously reported. As demonstrated in thrombospondindigestion experiments, the kringle domains and particularly K5 play an important role in promoting the rapid association of plasmin with thrombospondin.
MATERIALS AND METHODS Materials
p-Nitrophenyl p'-guanidinobenzoate hydrochloride (PNPGB), Na-benzoyl-DL-arginine p-nitroanilide hydrochloride (BAPNA), tranexamic acid (TEA) and e-aminohexanoic acid (eAHA) were purchased from Sigma. D-Phe-L-Pro-L-Arg-chloromethyl ketone (PPACK) was from Calbiochem. D-Val-L-Leu-L-Lys p-nitroanilide hydrochloride (S-2251) was from Kabi Vitrum, Stockholm, Sweden. Na125I was from Amersham International, and lodobeads were from Pierce.
Proteins
[Glu']Plasminogen was purified from human plasma by the method of Deutsch and Mertz [19] . The final preparations included carbohydrate variants I and II, with variant II present in slight excess. Miniplasminogen was prepared by digesting plasminogen with pig pancreatic elastase and purified by chromatography on lysine-Sepharose [20] .
Miniplasminogen and plasminogen were activated with lowmolecular-mass urokinase (Calbiochem). The concentration of active proteinase was determined by active-site titration [21] or by titration with a2AP. ac2M and a2AP were purified from human plasma by the methods of Imber and Pizzo [22] and Wiman [23] respectively.
Human thrombospondin was purified from outdated pooled human platelet concentrates kindly provided by the Virginia Blood Service (Richmond, VA, U.S.A.). The method of Santoro and Frazier [24] was followed except that the thrombin (5.0 nM) used to release platelet ac-granules was inactivated with 5.0 /1M PPACK. The thrombospondin was homogeneous as determined by SDS/PAGE. A single band with an apparent Mr < 400000 was present before reduction. The mobility of thrombospondin purified in this laboratory (with and without reduction) was identical to a preparation kindly provided by Dr. Deane Mosher (University of Wisconsin). The concentration of purified thrombospondin was determined by measuring the absorbance at 280 nm using a coefficient (A°'°m) of 9.1 [25] .
Radlo-lodinatlon Plasminogen and miniplasminogen were radio-iodinated with lodobeads as described by the manufacturer (Pierce). Desalting was performed on a Sephadex G-25 column (Pharmacia). The specific activities of 1251-plasminogen and 1251-miniplasminogen were 0.5-1. 4 IuCi//ttg of protein and 0.8-1.1 tCi/,tg of protein respectively. After activation with urokinase, the activities of '251-plasmin and 1251-miniplasmin were decreased by less than 5% compared with non-radio-iodinated proteinase, as determined by the rate of S-2251 hydrolysis.
Plasmin amidase activity in the presence of thrombospondin Plasmin (18 nM) and different concentrations of thrombospondin (0.2-1.2,M) were incubated in the sample cuvette of a Hewlett-Packard 8450 diode-array spectrophotometer for 5 min at 22 'C. S-2251 (0.09-0.72 mM) was then added and the absorbance at 406 nm was measured every 2 s for 200 s. The velocity of substrate hydrolysis was determined by transforming absorbance measurements using the first-derivative function (dA406/dt). Results were analysed by Lineweaver-Burk plots, which were uniformly linear with correlation coefficients ranging from 0.99 to 1.00.
The buffer for these amidase activity experiments and all other presented studies (except when specified) was 50 mM Tris/ HCl/150 mM NaCl/l mM CaCl2/0.05 % Tween 80, pH 7.6
(TBS-C-T). The hydrolysis of S-2251 by plasmin and the effects of thrombospondin on plasmin amidase activity were unchanged when Tween 80 was omitted from the buffer; however, high concentrations of thrombospondin (> 0.5 1M) could not be consistently maintained in solution without Tween 80.
In some amidase activity experiments, plasmin (18 nM) and thrombospondin (0.2-1.2,M) were incubated for 30 min (instead of 5 min) before addition of S-2251. In other studies, thrombospondin (0.2-1.2 ,uM) and S-2251 (0.54 mM) were added simultaneously to a cuvette containing plasmin (18 nM). Experiments which were used to generate Lineweaver-Burk plots were performed in quadruplicate. All other experiments were performed at least in duplicate.
Irreversible Inhibition of plasmin by thrombospondin
The inhibition of plasmin by thrombospondin detected by Hogg et al. [18] was irreversible in the presence of cAHA [18] . To detect this form of inhibition, plasmin (24 nM) was incubated with thrombospondin (260 and 400 nM) at 37 'C for 2 h in the presence and absence of 10 mM eAHA. Samples of each solution were removed at various times. S-2251 and eAHA were then added simultaneously at final concentrations of 0.54 mM and 25 mM respectively. Absorbance values were determined at 406 nm.
Thrombospondin digestion by plasmin and miniplasmin Plasmin or miniplasmin (18 nM) were incubated with thrombospondin (0.74 1tM) in the presence or absence of 10 mM TEA at 37 'C. Aliquots of the reaction mixtures were removed at various times. The proteinases were inactivated with 0.4 mM PNPGB and the samples were denatured in the presence of 22 mM dithiothreitol. SDS/PAGE was performed on 8 % (w/v) slabs using a Hepes-imidazole, pH 7.3, buffer system. Fragments were identified by comparison with Bio-Rad molecular-mass standards. The digestion of thrombospondin was also studied in the presence of 2 mM EDTA (no CaCl2).
Reaction of plasmin with oc2AP in the presence of thrombospondin Plasmin inhibition by a2AP in the presence of thrombospondin was studied by two different techniques. In the first set of experiments, plasmin (18 nM) and thrombospondin (0.1-0.4 ,uM) were incubated for 5 min at 22 'C. S-2251 (0.54 mM) was then added and the absorbance at 406 nm was determined every 2 s for 100 s to establish a baseline rate of substrate hydrolysis. After adding a2AP (18 nM From the Lineweaver-Burk plots shown in Figure 1 , kinetic parameters for the hydrolysis of S-2251 by plasmin were determined. The K. and kcat values in the absence of thrombospondin were 150+ 12 #M and 11.3 +0.3 s-1 respectively. In the presence of thrombospondin, the apparent kcat decreased and the apparent KM increased. The slopes from the Lineweaver-Burk graphs were plotted against the initial thrombospondin concentration, yielding a straight line (correlation coefficient, 0.99). This analysis indicated that thrombospondin is a linear mixed- type inhibitor ofS-225 1 hydrolysis. The dissociation constant (KI) for the interaction of plasmin with thrombospondin, assuming a single plasmin-binding site per thrombospondin homotrimer (intact or partially digested), was 0.5 ,uM. The characterization of thrombospondin as a linear mixedtype plasmin inhibitor may be explained if plasmin, which is bound to thrombospondin, has decreased affinity for S-225 1 and if S-225 1 binding to plasmin-thrombospondin complex does not result in p-nitroanilide generation. Owing to thrombospondin solubility, the number of experiments performed with thrombospondin concentrations exceeding the KI (0.5 #M) was limited.
Therefore, our analysis may not have been sufficient to rule out a low level of residual plasmin activity for the complex of plasmin with thrombospondin.
Irreversible plasmin Inhibition by thrombospondin
Plasmin (24 nM) was incubated with four separate preparations of purified thrombospondin (260 and 400 nM) for up to 2 h at 37 'C. At various times, plasmin amidase activity was determined by adding S-225 1 and eAHA simultaneously. The maximum loss of plasmin activity was less than 10o%, suggesting that the binding of plasmin to thrombospondin was reversible by eAHA. In control experiments, plasmin amidase activity was determined after incubating plasmin for 2 h in the absence of thrombospondin or for 2 h in the presence of thrombospondin and 10 mM eAHA. In both cases, plasmin amidase activity was decreased by less than 100%.
Thrombospondin digestion by plasmin and miniplasmin
Thrombospondin monomer (Mr 150000) was relatively free of contaminants as demonstrated by SDS/PAGE (Figure 2 ). When incubated with plasmin (18 nM) for up to 2 h, the intact monomer was slowly digested, yielding two major fragments with apparent Mr values of 125000 and 35000. Similar thrombospondin fragmentation patterns have been generated with other proteinases [26] ; the heparin-binding domain (Mr 35000) is readily cleaved from the remainder of the protein.
Thrombospondin was incubated with plasmin in 10 mM TEA. This concentration of TEA almost completely inhibits the digestion offibrin monomer by plasmin without affecting plasmin amidase activity [27] . As shown in Figure 2 , thrombospondin digestion was partially inhibited by 10 mM TEA; however, the inhibition was less complete than with fibrin.
Miniplasmin digested thrombospondin into products that were comparable with the plasmin products, as determined by SDS/ PAGE. The rate of digestion by miniplasmin was slightly slower. TEA (10 mM) significantly inhibited thrombospondin digestion by miniplasmin; however, inhibition was not complete. Since miniplasmin lacks K1-K4, the inhibitory activity ofTEA suggests that binding of the plasmin K5 domain to thrombospondin is critical for thrombospondin digestion.
Thrombospondin digestion in the presence of EDTA Thrombospondin was incubated with plasmin and miniplasmin in the presence of 2.0 mM EDTA (Figure 3) . EDTA chelates calcium which is bound to thrombospondin; the loss of calcium forces the structure of thrombospondin to unwind and open [28, 29] . The resulting conformation is more susceptible to digestion by most proteinases and as shown in Figure 3 , cleavage of thrombospondin by plasmin and miniplasmin was more rapid as well. The major products were not substantially different in the presence of EDTA; however, the inhibitory activity of TEA was more apparent. These results strongly suggest that the lysine-binding sites, and in particular K5, assist in the anchoring of plasmin and miniplasmin to thrombospondin and the subsequent digestion of the substrate.
The thrombospondin-digestion experiments suggested that plasmin may interact with both conformations of thrombospondin (in calcium or in EDTA) in a manner which is at least partially dependent on K5. To study the binding of plasmin to thrombospondin in the presence of EDTA further, the two proteins were pre-incubated for 5 min and then reacted with S-2251. In three separate experiments, thrombospondin at concentrations up to 0.4 ,uM decreased the amidase activity of plasmin in EDTA. The extent of the decrease was within 150 of that demonstrated in TBS-C-T buffer (results not shown).
Reaction of plasmin with ex2AP
a2AP is the primary inhibitor of plasmin in human plasma; the inhibition rate constant is approx. 2.0 x 107 M-1 s-1 [30] . Rapid inhibition depends on non-covalent association of a2AP with the K1-K3 domains of plasmin [7, 30] . The rate of plasmin inhibition by a2AP in the presence of thrombospondin was studied initially using a continuous assay measuring chromogenic-substrate hydrolysis. When plasmin (18 nM) and a2AP (18 nM) were 1251-Plasmin (18 nM) was incubated alone (-) or with 1.2 ,uM thrombospondin (0) and then with a2AP (0.9 jiM) at 22°C. cc2AP-plasmin-complex formation was detected by SDS/PAGE. allowed to react in the absence of thrombospondin, the plasmin activity was completely inhibited within less than 40 s; the halflife for plasmin inhibition (to.5) was 13.2 + 3.0 s (Table 1 ).
In the presence of thrombospondin (0.1-0.4 ,uM), the initial plasmin activity was decreased as expected; however, the residual plasmin activity was rapidly and completely inhibited by a2AP. A substantial decrease in the rate of reaction of plasmin with a2AP was not detected. In this regard, thrombospondin differed from fibrin or plasmin(ogen) cell-surface receptors (8, 9] . Higher concentrations of thrombospondin (up to 1.2 uM) were also studied. In these experiments, the reaction of plasmin with a2AP proceeded rapidly to completion; however, due to the low level of initial plasmin activity (before addition of a2AP), to05 values were not determined.
Because of the significant decrease in plasmin amidase activity upon binding thrombospondin, the chromogenic-substrate method used to study the reaction of plasmin with ac2AP may have detected only plasmin which was free in solution. This would explain why thrombospondin altered the apparent rate of reaction of plasmin with a2AP minimally. To account for all of the plasmin present in the system, a2AP (0.9 ,uM) was reacted with 125I-plasmin (18 nM) which had been pre-incubated with 1.2 ,uM thrombospondin for 5 min. a2AP-plasmin complex was detected by SDS/PAGE. As shown in Figure 4 , about 50 % of the 125I-plasmin reacted with a2AP at nearly the same rate as determined in the absence of thrombospondin. The remaining 125I-plasmin reacted more slowly, but apparently as a first-order process. Within 20 min, the reaction of plasmin with a2AP in the presence of thrombospondin was essentially complete. If plasmin which is bound to thrombospondin is completely incapable of reacting with a2AP, then the later phase of the reaction shown in Figure 4 provides a minimum estimate of the plasmin-thrombospondin complex dissociation rate constant Reaction of plasmin with ;2M a2M is the second major inhibitor of plasmin in human plasma; unlike a2AP, the mechanism by which a2M inhibits plasmin does not involve the plasmin kringle domains [27, 31] . '25I-Plasmin (18 nM) was incubated with different concentrations of thrombospondin for 5 min and then reacted with a2M (180 nM). The curves showing formation of a2M-plasmin complex were nonlinear ( Figure 5 ). In each experiment, a substantial fraction of the plasmin was relatively resistant to reaction with a2M. Although the SDS/PAGE method was not entirely sensitive to small differences in the size of the a2M-resistant fraction, the greatest (Figure 6 ). Thrombospondin increased the recovery of a2AP-plasmin complex in a concentrationdependent manner. This shift in recovery reflects plasmin that did not react with a2M in the first 5 min and therefore was probably bound to thrombospondin. These results confirm that plasmin that is resistant to inhibition by proteinase inhibitors, due to association with thrombospondin, is not irreversibly inactivated.
DISCUSSION
Thrombospondin is an adhesive glycoprotein which may be found at many sites in vivo, including the surfaces of cells such as platelets, endothelial cells, fibroblasts, smooth muscle cells, monocytes, and macrophages, in the extracellular matrix, basement membranes and in fibrin blood clots [14, 15, 26] . In all of these sites, thrombospondin co-exists with proteinases such as plasmin. The proteinases remodel cellular microenvironments, support tumour-cell invasion, alter the progress of bacterial infection and promote the immune response. In order for plasmin to function, plasminogen must be activated and then protected from the rapid antiplasmins, a2AP and a2M.
The effects of thrombospondin on plasminogen activation have been studied previously [6] . Thrombospondin accelerates the activation of plasminogen by t-PA. Nevertheless, when the lysis of fibrin by mixtures oft-PA and plasminogen was examined, thrombospondin was an inhibitor [16] . The present investigation was designed to examine the effects of thrombospondin on the activity of plasmin directly.
All of the studies presented here confirm that plasmin binds to thrombospondin in solution. This association results in thrombospondin digestion, indicating the involvement of the plasmin active site. TEA inhibited the digestion of thrombospondin when present at concentrations that were insufficient to inhibit plasmin amidase activity. This result indicates that the plasmin kringle domains are also involved in the plasmin-thrombospondin interaction. From among the kringle domains, we propose that K5 plays an important role, since TEA inhibited thrombospondin digestion by plasmin and miniplasmin similarly. This conclusion supports the work of DePoli et al. [17] .
How thrombospondin affects the activity of plasmin has not been resolved. The studies presented here indicate that thrombospondin is a plasmin inhibitor, as demonstrated by Hogg et al. [18] ; however, the interaction described here is different from that described by Hogg et al. [18] in the following ways: (1) association occurs relatively rapidly so that an apparent equilibrium is achieved in about 3 min; (2) binding is completely reversible in the presence of eAHA or other antiplasmins; and (3) the affinity of the plasmin-thrombospondin interaction described here is much lower (0.5 ,M) than previously reported (< 1.0 nM).
One model to explain our results intimately links the roles of thrombospondin as a plasmin inhibitor and a plasmin substrate. When plasmin binds thrombospondin, cleavage of susceptible peptide bonds occurs with slow turnover. While enzyme (plasmin) and substrate (thrombospondin) are engaged in what is apparently a multiple-site interaction, the plasmin expresses little or no activity against other substrates/inhibitors including S-2251, a2AP and a2M.
A concern regarding interpretation of the chromogenicsubstrate-hydrolysis experiments was the possibility that our thrombospondin preparations might be contaminated by trace levels of an irreversible plasmin inhibitor. This concern was addressed in experiments with eAHA. When eAHA was added with S-225 1, the decrease in plasmin amidase activity was reversed. The reversibility of the plasmin-thrombospondin interaction was supported by additional experiments with a2AP and n F-i a2M. Under a variety of conditions, we demonstrated that plasmin which was apparently bound to thrombospondin could be completely transferred to x2AP in a relatively short period of time. Since plasmin must express proteolytic activity in order to react with a2AP, irreversible plasmin inhibition could not have occurred. There are two possible explanations for the complete reaction ofplasmin with a2AP after pre-incubation with thrombospondin; either plasmin that is bound to thrombospondin reversibly dissociates and then reacts with a2AP, or plasmin retains limited proteolytic activity when bound to thrombospondin which was not detected in our assays (Figure 1) . While the first explanation is favoured, these two possibilities are not mutually exclusive.
It is conceivable that the relatively rapid, low-affinity, reversible binding of plasmin to thrombospondin described here could be followed by a second step in which an irreversible complex, such as that described by Hogg et al. [18] , is formed. In experiments with four separate thrombospondin preparations purified in this laboratory, we were not able to demonstrate irreversible plasmin inhibition; however, we could demonstrate irreversible plasmin binding to the thrombospondin provided by Dr. Mosher (results not shown). The reason why this thrombospondin, which was equivalent to our preparations by SDS/PAGE, was able to bind plasmin with higher affinity is unclear and currently under investigation.
The slow digestion of thrombospondin by plasmin coupled with the plasmin inhibitory activity of thrombospondin suggests a novel role for this protein in the regulation of fibrinolysis and other plasmin-mediated biological processes. By binding plasmin in a manner that eliminates or significantly inhibits catalytic activity, thrombospondin functions as an antiplasmin. Since the thrombospondin-plasmin complex is at least initially reversible, thrombospondin may carry plasmin in a latent form into a fibrin clot or into the extracellular matrix. While in the latent, thrombospondin-associated state, plasmin is resistant to a2AP. Therefore, the latent state provides a mechanism for enhanced survival of plasmin in proteinase-inhibitor-rich environments and the delivery of plasmin to sites where plasminogen activators may not be present.
